Literature DB >> 18683247

Evidence for disruption of sphingolipid metabolism in schizophrenia.

Sujatha Narayan1, Steven R Head, Timothy J Gilmartin, Brian Dean, Elizabeth A Thomas.   

Abstract

As the field of glycobiology grows, important roles for glycolipids and glycoproteins in neurological disorders are being increasingly appreciated. However, few studies have explored the involvement of these molecules in the pathology of psychiatric illnesses. We investigated molecular differences related to glycobiology in subjects with schizophrenia by analyzing gene expression profiles using a focused glycogene chip, a custom-designed oligonucleotide array containing genes encoding proteins related to glycobiology, including glycosyltransferases, carbohydrate-binding proteins, proteoglycans, and adhesion molecules. We measured expression profiles in prefrontal cortical (BA46) samples from schizophrenic subjects and matched controls. We find differential expression of genes particularly related to glycosphingolipid/sphingolipid metabolism and N- and O-linked glycan biosynthesis in subjects with schizophrenia. Expression decreases of seven genes associated with these pathways, UGT8, SGPP1, GALC, B4GALT6, SPTLC2, ASAH1, and GAL3ST1, were validated by quantitative PCR in schizophrenic subjects with short-term illness. Only one of these genes, SPTLC2, showed differential expression in chronic schizophrenic subjects, although an increase in expression was observed. Covariate analysis showed that the expression of five of these genes was significantly positively correlated with age in schizophrenic, but not control, subjects. These changing patterns of expression could represent an adaptive response to pathology with disease progression or a compensatory effect of antipsychotic medication, although no significant correlations between gene expression levels and drug doses were observed. Disruption of sphingolipid metabolism early in illness could result in widespread downstream effects encompassing diverse pathological deficits already described in schizophrenia, especially those involving myelination and oligodendrocyte function; hence, this system may represent an important link in schizophrenia pathology. 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18683247      PMCID: PMC2606914          DOI: 10.1002/jnr.21822

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  42 in total

Review 1.  The impact of glycobiology on medicine.

Authors:  J Axford
Journal:  Trends Immunol       Date:  2001-05       Impact factor: 16.687

2.  Evidence for white matter abnormalities in schizophrenia.

Authors:  Marek Kubicki; Robert W McCarley; Martha E Shenton
Journal:  Curr Opin Psychiatry       Date:  2005-03       Impact factor: 4.741

3.  Three putative N-glycosylation sites within the murine 5-HT3A receptor sequence affect plasma membrane targeting, ligand binding, and calcium influx in heterologous mammalian cells.

Authors:  Phillip L Quirk; Suma Rao; Bryan L Roth; Ruth E Siegel
Journal:  J Neurosci Res       Date:  2004-08-15       Impact factor: 4.164

4.  The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia.

Authors:  F M Benes; D Matzilevich; R E Burke; J Walsh
Journal:  Mol Psychiatry       Date:  2006-03       Impact factor: 15.992

Review 5.  Genome wide gene expression studies in mood disorders.

Authors:  Adolfo Sequeira; Gustavo Turecki
Journal:  OMICS       Date:  2006

Review 6.  Intracellular signal transduction pathways activated by ceramide and its metabolites.

Authors:  Peter P Ruvolo
Journal:  Pharmacol Res       Date:  2003-05       Impact factor: 7.658

7.  Dopamine D1 receptor, D2 receptor, proenkephalin A and substance P gene expression in the caudate nucleus of control and schizophrenic tissue: a quantitative cellular in situ hybridisation study.

Authors:  K A Harrington; S J Augood; R L Faull; P J McKenna; P C Emson
Journal:  Brain Res Mol Brain Res       Date:  1995-11

8.  Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin.

Authors:  Marcus O W Grimm; Heike S Grimm; Andreas J Pätzold; Eva G Zinser; Riikka Halonen; Marco Duering; Jakob A Tschäpe; Bart De Strooper; Ulrike Müller; Jie Shen; Tobias Hartmann
Journal:  Nat Cell Biol       Date:  2005-11       Impact factor: 28.824

Review 9.  White matter changes in schizophrenia: evidence for myelin-related dysfunction.

Authors:  Kenneth L Davis; Daniel G Stewart; Joseph I Friedman; Monte Buchsbaum; Philip D Harvey; Patrick R Hof; Joseph Buxbaum; Vahram Haroutunian
Journal:  Arch Gen Psychiatry       Date:  2003-05

10.  Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?

Authors:  Pavel Katsel; Celeste Li; Vahram Haroutunian
Journal:  Neurochem Res       Date:  2007-03-07       Impact factor: 3.996

View more
  36 in total

1.  Human and rodent temporal lobe epilepsy is characterized by changes in O-GlcNAc homeostasis that can be reversed to dampen epileptiform activity.

Authors:  Richard G Sánchez; R Ryley Parrish; Megan Rich; William M Webb; Roxanne M Lockhart; Kazuhito Nakao; Lara Ianov; Susan C Buckingham; Devin R Broadwater; Alistair Jenkins; Nihal C de Lanerolle; Mark Cunningham; Tore Eid; Kristen Riley; Farah D Lubin
Journal:  Neurobiol Dis       Date:  2019-01-06       Impact factor: 5.996

2.  Altered fucosyltransferase expression in the superior temporal gyrus of elderly patients with schizophrenia.

Authors:  Toni M Mueller; Stefani D Yates; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2016-10-20       Impact factor: 4.939

Review 3.  Extracellular matrix proteomics in schizophrenia and Alzheimer's disease.

Authors:  Manveen K Sethi; Joseph Zaia
Journal:  Anal Bioanal Chem       Date:  2016-09-06       Impact factor: 4.142

4.  Harnessing the power of yeast to elucidate the role of sphingolipids in metabolic and signaling processes pertinent to psychiatric disorders.

Authors:  Shyamalagauri Jadhav; Miriam L Greenberg
Journal:  Clin Lipidol       Date:  2014-11-01

Review 5.  Aberrant glycosylation in schizophrenia: a review of 25 years of post-mortem brain studies.

Authors:  Sarah E Williams; Robert G Mealer; Edward M Scolnick; Jordan W Smoller; Richard D Cummings
Journal:  Mol Psychiatry       Date:  2020-05-13       Impact factor: 15.992

6.  Abnormal N-acetylglucosaminyltransferase expression in prefrontal cortex in schizophrenia.

Authors:  Jordyn M Kippe; Toni M Mueller; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2015-06-20       Impact factor: 4.939

7.  Profiling of lipidomics before and after antipsychotic treatment in first-episode psychosis.

Authors:  Liisa Leppik; Madis Parksepp; Sven Janno; Kati Koido; Liina Haring; Eero Vasar; Mihkel Zilmer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-02       Impact factor: 5.270

8.  A cytogenetic abnormality and rare coding variants identify ABCA13 as a candidate gene in schizophrenia, bipolar disorder, and depression.

Authors:  Helen M Knight; Benjamin S Pickard; Alan Maclean; Mary P Malloy; Dinesh C Soares; Allan F McRae; Alison Condie; Angela White; William Hawkins; Kevin McGhee; Margaret van Beck; Donald J MacIntyre; John M Starr; Ian J Deary; Peter M Visscher; David J Porteous; Ronald E Cannon; David St Clair; Walter J Muir; Douglas H R Blackwood
Journal:  Am J Hum Genet       Date:  2009-12       Impact factor: 11.025

9.  Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia.

Authors:  Deborah Bauer; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2009-08-27       Impact factor: 4.939

10.  Genetic determinants of circulating sphingolipid concentrations in European populations.

Authors:  Andrew A Hicks; Peter P Pramstaller; Asa Johansson; Veronique Vitart; Igor Rudan; Peter Ugocsai; Yurii Aulchenko; Christopher S Franklin; Gerhard Liebisch; Jeanette Erdmann; Inger Jonasson; Irina V Zorkoltseva; Cristian Pattaro; Caroline Hayward; Aaron Isaacs; Christian Hengstenberg; Susan Campbell; Carsten Gnewuch; A Cecilej W Janssens; Anatoly V Kirichenko; Inke R König; Fabio Marroni; Ozren Polasek; Ayse Demirkan; Ivana Kolcic; Christine Schwienbacher; Wilmar Igl; Zrinka Biloglav; Jacqueline C M Witteman; Irene Pichler; Ghazal Zaboli; Tatiana I Axenovich; Annette Peters; Stefan Schreiber; H-Erich Wichmann; Heribert Schunkert; Nick Hastie; Ben A Oostra; Sarah H Wild; Thomas Meitinger; Ulf Gyllensten; Cornelia M van Duijn; James F Wilson; Alan Wright; Gerd Schmitz; Harry Campbell
Journal:  PLoS Genet       Date:  2009-10-02       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.